biostudies-literatureUnknown4(1)Kapoor A<h4>Introduction</h4>ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India.<h4>Methods</h4>An audit of a prospectively collected database of patients with advanced ALK-positive NSCLC treated from January 2013 to March 2018 was conducted. The SPSS version 20.0 was used for statistical analysis.<h4>Results</h4>A total of 441 patients were available for analysis; 62.5% were males, median age was 50 (range: 19-75) years, and 78.3% had Eastern Cooperative Oncology Group performance status of 0 to 1. When all the lines of therapies were included in the analysis, ALK inhibitors could be used in 379 (85.9%) of thJTO clinical and research reports100443https://www.ebi.ac.uk/biostudies/studies/S-EPMC9841022biostudies-literatureClinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings.PMC9841022Shetty OJoshi AJanu AKumar RPatil VSingh AKMahajan ANoronha VChougule AMenon NPai TKapoor APrabhash KKumar AfalseClinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings.<h4>Introduction</h4>ALK inhibitors are one of the success stories in precision medicine for treating patients with advanced ALK-positive NSCLC. Nevertheless, developing countries have substantial constraints in using ALK inhibitors, with limited data from India.<h4>Methods</h4>An audit of a prospectively collected database of patients with advanced ALK-positive NSCLC treated from January 2013 to March 2018 was conducted. The SPSS version 20.0 was used for statistical analysis.<h4>Results</h4>A total of 441 patients were available for analysis; 62.5% were males, median age was 50 (range: 19-75) years, and 78.3% had Eastern Cooperative Oncology Group performance status of 0 to 1. When all the lines of therapies were included in the analysis, ALK inhibitors could be used in 379 (85.9%) of th2023-01-01T00:00:00Z2023 Jan2026-03-15T13:47:48.884Z2025-04-04T14:28:10.249ZS-EPMC98410223665488110.1016/j.jtocrr.2022.100443